Yingyong Hou

5.6k total citations
233 papers, 2.9k citations indexed

About

Yingyong Hou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Yingyong Hou has authored 233 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 88 papers in Oncology and 82 papers in Surgery. Recurrent topics in Yingyong Hou's work include Gastrointestinal Tumor Research and Treatment (49 papers), Gastric Cancer Management and Outcomes (40 papers) and Sarcoma Diagnosis and Treatment (36 papers). Yingyong Hou is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (49 papers), Gastric Cancer Management and Outcomes (40 papers) and Sarcoma Diagnosis and Treatment (36 papers). Yingyong Hou collaborates with scholars based in China, United States and Italy. Yingyong Hou's co-authors include Dongxian Jiang, Chen Xu, Shaohua Lu, Yun-shan Tan, Weiqi Lu, Lijie Tan, Yuhong Zhou, Haiying Zeng, Hai Wang and Chunxue Bai and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Yingyong Hou

216 papers receiving 2.9k citations

Peers

Yingyong Hou

ONCOL

PRM

SURGE

Hongwei Zhang China

Makoto Sohda Japan

In‐Gu Do South Korea

Carsten Boltze Germany

Kazuyuki Ishida Japan

Jiang Yu China

David F. Schaeffer Canada

Haijun Deng China

Susumu Saigusa Japan

Hongwei Zhang China

Yingyong Hou

895 ×0.8

606 ×0.6

ONCOL

847 ×0.8

PRM

701 ×0.9

SURGE

422 ×0.7

Citations per year, relative to Yingyong Hou Yingyong Hou (= 1×) peers Hongwei Zhang

Countries citing papers authored by Yingyong Hou

Since Specialization

Citations

This map shows the geographic impact of Yingyong Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingyong Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingyong Hou more than expected).

Fields of papers citing papers by Yingyong Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingyong Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingyong Hou. The network helps show where Yingyong Hou may publish in the future.

Co-authorship network of co-authors of Yingyong Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Yingyong Hou. A scholar is included among the top collaborators of Yingyong Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingyong Hou. Yingyong Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Qiao, Xiaomeng Xu, Dongxian Jiang, et al.. (2025). Integrated proteogenomic characterization of ampullary adenocarcinoma. Cell Discovery. 11(1). 2–2.

Gao, Weijie, et al.. (2025). A turn on fluorescent probe for nitroreductase activity and its application in real-time imaging of tumor hypoxia. Talanta. 290. 127804–127804. 2 indexed citations

Liu, Xiaoli, Rongkui Luo, Zhe Jian, et al.. (2025). USP38 functions as an oncoprotein by downregulating the p53 pathway through deubiquitination and stabilization of MDM2. Cell Death and Differentiation. 32(6). 1128–1141. 2 indexed citations

Zhang, Jiaxing, et al.. (2025). Research on the Impact and Path of Human-Machine Collaborative Decision-Making on Dualistic Innovations. IEEE Access. 13. 88065–88077.

Ma, Chao, Zhe Wu, Yingyong Hou, et al.. (2025). Continuous photocatalytic C–C coupling achieved using palladium anchored to a covalent organic framework. Chemical Communications. 61(39). 7085–7088.

Yuan, Wei, et al.. (2025). A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration. Diagnostic Pathology. 20(1). 31–31.

Luo, Rongkui, Wen Huang, Wei Yuan, et al.. (2024). IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer. Journal of Cancer Research and Clinical Oncology. 150(7). 363–363. 1 indexed citations

Hang, Xiang, Rongkui Luo, Yunzhi Wang, et al.. (2024). Proteogenomic insights into the biology and treatment of pan-melanoma. Cell Discovery. 10(1). 78–78. 3 indexed citations

Zhao, Yingying, Jiali Qian, Hanxing Tong, et al.. (2024). TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway. Cellular Oncology. 48(2). 455–470. 1 indexed citations

10.

Li, Lingling, Dongxian Jiang, Qiao Zhang, et al.. (2024). Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression. Cancer Research. 84(17). 2888–2910. 3 indexed citations

11.

Sun, Qi, et al.. (2023). Comparison and validation of different risk models for papillary renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 41(8). 358.e1–358.e7. 1 indexed citations

12.

Zhang, Qiang, et al.. (2023). New insight on the correlation of immune landscapes with immune markers expression in different risk classification of gastrointestinal stromal tumors. Journal of Gastroenterology. 58(6). 527–539.

13.

Luo, Zhiguo, Xin Liu, Xiaoying Zhang, et al.. (2023). 1208MO A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary. Annals of Oncology. 34. S712–S712. 2 indexed citations

14.

Zhang, Lili, Rui Xue, Jie Huang, et al.. (2023). Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 482(3). 567–580. 9 indexed citations

15.

Zhuang, Rongyuan, Xi Guo, Yang You, et al.. (2022). Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial. Clinical Cancer Research. 28(24). 5290–5296. 11 indexed citations

16.

Xu, Chen, Miaomiao Sun, Hongfang Jin, et al.. (2022). Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagnostic Pathology. 17(1). 54–54. 4 indexed citations

17.

Zhang, Xinyu, Chun Li, Maosong Ye, et al.. (2021). Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer. Frontiers in Oncology. 11. 602402–602402. 5 indexed citations

18.

Sun, Xiaomao, Wei Yuan, Min Fu, et al.. (2020). [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].. PubMed. 23(9). 880–887. 2 indexed citations

19.

Xu, Chen, Yalan Liu, Dongxian Jiang, et al.. (2017). HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks. Histopathology. 71(4). 570–579. 6 indexed citations

20.

Yang, Guo‐Yuan, Michelle Lacey, Jeffrey I. Gordon, et al.. (2014). Education. Modern Pathology. 27. 145–150. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact